Silke Tribius1, Markus Hoffmann. 1. Department of Radiotherapy and Radio-Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. tribius@uke.uni-hamburg.de
Abstract
BACKGROUND: The causal link between cervical cancer and human papilloma virus (HPV) is well known. It is now becoming clear that some types of squamous-cell carcinoma of the head and neck, particularly oropharyngeal carcinoma (OPC), are also linked to HPV infection. The development of vaccines against certain HPV genotypes has changed the management strategy for HPV-associated diseases of the uterine cervix. An analogous approach is now being considered for the prevention of HPV-associated diseases of the head and neck. METHOD: We review pertinent articles retrieved by a selective search of the literature for phase II and III trials providing evidence about a possible effect of HPV status on the survival rates of patients with OPC. Seven trials fulfilled our search criteria: four phase III trials with retrospective HPV analysis and three phase II trials with retrospective and prospective HPV analysis. RESULTS: Patients with HPV-positive OPC survive significantly longer than those with HPV-negative OPC. Tobacco smoking has been identified as a negative prognostic factor in patients with either HPV-negative or HPV-positive disease. CONCLUSION: The established treatment strategy for OPC in patients with and without the traditional risk factors (tobacco and alcohol consumption) is now being reconsidered in the light of what we have learned about the role of HPV infection. Ongoing and projected clinical trials with risk-factor stratification may soon lead to changes in treatment. Further study is needed to answer the question whether HPV infection in the head and neck region is carcinogenic.
BACKGROUND: The causal link between cervical cancer and human papilloma virus (HPV) is well known. It is now becoming clear that some types of squamous-cell carcinoma of the head and neck, particularly oropharyngeal carcinoma (OPC), are also linked to HPV infection. The development of vaccines against certain HPV genotypes has changed the management strategy for HPV-associated diseases of the uterine cervix. An analogous approach is now being considered for the prevention of HPV-associated diseases of the head and neck. METHOD: We review pertinent articles retrieved by a selective search of the literature for phase II and III trials providing evidence about a possible effect of HPV status on the survival rates of patients with OPC. Seven trials fulfilled our search criteria: four phase III trials with retrospective HPV analysis and three phase II trials with retrospective and prospective HPV analysis. RESULTS:Patients with HPV-positive OPC survive significantly longer than those with HPV-negative OPC. Tobacco smoking has been identified as a negative prognostic factor in patients with either HPV-negative or HPV-positive disease. CONCLUSION: The established treatment strategy for OPC in patients with and without the traditional risk factors (tobacco and alcohol consumption) is now being reconsidered in the light of what we have learned about the role of HPV infection. Ongoing and projected clinical trials with risk-factor stratification may soon lead to changes in treatment. Further study is needed to answer the question whether HPV infection in the head and neck region is carcinogenic.
Authors: Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245
Authors: Orlando Guntinas-Lichius; Thomas Wendt; Jens Buentzel; Dirk Esser; Peter Lochner; Andreas Mueller; Stefan Schultze-Mosgau; Annelore Altendorf-Hofmann Journal: J Cancer Res Clin Oncol Date: 2010-01 Impact factor: 4.553
Authors: Silke Tribius; Anna S Ihloff; Thorsten Rieckmann; Cordula Petersen; Markus Hoffmann Journal: Cancer Lett Date: 2011-03-04 Impact factor: 8.679
Authors: M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen Journal: Ann Oncol Date: 2011-02-11 Impact factor: 32.976
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt Journal: BMJ Date: 2010-07-20
Authors: Markus Hoffmann; Anna Sophie Ihloff; Tibor Görögh; Jan B Weise; Asita Fazel; Matthias Krams; Werner Rittgen; Elisabeth Schwarz; Tomas Kahn Journal: Int J Cancer Date: 2010-10-01 Impact factor: 7.396
Authors: M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann Journal: HNO Date: 2016-07 Impact factor: 1.284
Authors: Philipp Baumeister; Maximilian Reiter; Christian Welz; Sven Becker; Christian Betz; Ulrich Harréus Journal: J Cancer Res Clin Oncol Date: 2014-03-11 Impact factor: 4.553
Authors: Christian R Salazar; Nicole Anayannis; Richard V Smith; Yanhua Wang; Missak Haigentz; Madhur Garg; Bradley A Schiff; Nicole Kawachi; Jordan Elman; Thomas J Belbin; Michael B Prystowsky; Robert D Burk; Nicolas F Schlecht Journal: Int J Cancer Date: 2014-04-17 Impact factor: 7.396
Authors: Emmanuel A Oga; Lisa M Schumaker; Biodun Sulyman Alabi; Darlington Obaseki; Aniefon Umana; Ima-Abasi Bassey; Godwin Ebughe; Olabode Oluwole; Teniola Akeredolu; Sally N Adebamowo; Patrick Dakum; Kevin Cullen; Clement A Adebamowo Journal: PLoS One Date: 2016-04-06 Impact factor: 3.240